The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2024 | Sequencing CAR T-cells and bispecific antibodies in the treatment of multiple myeloma
Roberto Mina, MD, University of Turin, Turin, Italy, speaks about the sequencing of immunotherapies in the treatment of multiple myeloma. He emphasizes the lack of data on sequencing but highlights that it is better to use CAR T-cells before bispecific antibodies. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
